The World Market for Ovarian Cancer Drugs to 2030: Breakthroughs in Combination Drug Therapy Transforming Standards of Care
02 mai 2024 07h42 HE
|
Research and Markets
Dublin, May 02, 2024 (GLOBE NEWSWIRE) -- The "Ovarian Cancer Drugs Market Size and Forecast 2020-2030 by Type, Drug Class, Distribution Channel, and Geography" report has been added to ...
[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
27 mars 2024 14h30 HE
|
Custom Market Insights
Austin, TX, USA, March 28, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “PARP Inhibitors Market Size, Trends and Insights By Type (Olaparib, Rucaparib,...
Prostate Cancer Drugs Global Market Report 2024: Emerging Combination Therapies and Geographic Expansion to Propel the Global Prostate Cancer Drugs Market Through 2028
22 janv. 2024 16h58 HE
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Prostate Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This recent comprehensive study sheds...
Olaparib Reduces Organ Damage in Sepsis
13 sept. 2021 10h00 HE
|
Experimental Biology and Medicine
WASHINGTON, Sept. 13, 2021 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 246, Issue 17, September, 2021) examines the role of olaparib in sepsis. The...
Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019
01 avr. 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
10 sept. 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...